Patient Activity Scale II (PAS II) for Rheumatoid Arthritis

Why use it

Measurement-based care with regular quantitative disease activity assessment is essential for achieving treat-to-target (T2T) goals in RA. The PAS II provides a rapid, validated, fully patient-reported composite measure that does not require a physical joint examination, making it feasible for every clinic visit without increasing physician time. Its components — pain, function, and global health — capture the patient's disease experience across all dimensions. The PAS II correlates well with DAS28 (r=0.72) and responds to treatment change, enabling titration of biologic and csDMARD therapy.

About

The Patient Activity Scale II (PAS II) is a validated composite disease activity measure for rheumatoid arthritis (RA) developed by Wolfe and Michaud, published in 2005. Unlike the Disease Activity Score (DAS28), which requires a trained examiner to perform a joint count, the PAS II is entirely patient-reported and can be completed in the waiting room before a clinic visit, enabling efficient measurement-based care. The PAS II incorporates three domains: (1) pain VAS (0–10 cm visual analog scale), (2) HAQ-II (Health Assessment Questionnaire II) — an 8-item functional disability measure, and (3) global assessment VAS (0–10 cm) representing the patient's overall assessment of disease activity. The composite score ranges from 0 to 10 and is calculated using a validated formula. Validated thresholds divide patients into remission, low, moderate, and high disease activity states, correlating closely with DAS28 and RAPID3 thresholds. The PAS II is endorsed by the ACR as an acceptable disease activity measure for use in clinical practice and for rheumatology quality reporting programs.

When to use

• Every rheumatology clinic visit for patients with established RA — administered in the waiting room before the physician encounter
• Baseline documentation before initiating or changing DMARD therapy
• Serial monitoring during treat-to-target (T2T) RA management — recommend reassessment every 1–3 months until low disease activity or remission achieved, then every 3–6 months
• Determining treatment response to conventional synthetic DMARDs (methotrexate, leflunomide) or biologic/targeted synthetic DMARDs (TNFi, IL-6i, JAKi)
• Quality reporting and rheumatology registry documentation
• In patients with limitations to physical joint examination (obesity, lymphedema, prosthetic joints) where PAS II provides validated activity data without examiner bias

Formula

Pearls & pitfalls

• The HAQ-II is the functional disability component of PAS II — it asks about 8 specific physical activities (dressing, arising, eating, walking, hygiene, reach, grip, activities) each rated 0–3. HAQ-II = mean of 8 items.
• PAS II correlates well with DAS28-ESR (r=0.72) and DAS28-CRP (r=0.70) in validation studies — making it a practical surrogate for examiner-based scores when joint counts are not available.
• The PAS II remission threshold (≤0.25) is more stringent than DAS28 remission (<2.6) — reflecting that patient-reported outcomes capture residual symptoms even when joint counts are low.
• PAS II is fully patient-reported — it avoids examiner-specific variability in joint counts (examiner unreliability is a known limitation of DAS28 in real-world practice).
• In the 2022 ACR RA treatment guidelines, measurement-based care using any validated disease activity measure (PAS II, CDAI, DAS28, RAPID3) is a Class I recommendation.
• Always assess the individual components: a patient with PAS II in moderate range due primarily to high pain but low HAQ-II may have a different clinical picture (fibromyalgia overlap, poor sleep) than one with high HAQ-II (structural damage).
• PAS II is particularly useful in large rheumatology practices and telemedicine encounters where formal joint counts are logistically challenging.

Next steps

PAS II 0–0.25 (Remission): Continue current therapy. No dose escalation needed. Discuss maintenance therapy duration (stable DMARDs ≥6 months in remission before considering taper). PAS II 0.26–3.7 (Low Disease Activity): Continue current therapy if stable. Consider taper if sustained LDA ≥6 months. PAS II 3.71–7.99 (Moderate Disease Activity): Optimize current therapy (dose escalation of methotrexate up to 25 mg/week). If inadequate response after 3–6 months: add or switch biologic or JAK inhibitor. PAS II ≥8 (High Disease Activity): Treat-to-target — switch or escalate therapy urgently. Combination DMARD therapy, biologic initiation, or switch of biologic mechanism. Rheumatologist review within 4–6 weeks.

Evidence

Wolfe F, Michaud K. The Patient Activity Scale-II (PAS-II): it is the preferred patient activity scale. Rheumatology (Oxford). 2005;44(5):666-670. Validation in National Data Bank for Rheumatic Diseases (NDB) cohort. Correlation with DAS28-ESR r=0.72. ACR/EULAR 2022 RA Management Recommendations endorse routine disease activity measurement using validated tools including PAS II.

References

1. Wolfe F, Michaud K. The Patient Activity Scale-II (PAS-II): it is the preferred patient activity scale. Rheumatology (Oxford). 2005;44(5):666-670. — link
2. Anderson J et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res. 2012;64(5):640-647. — link
3. Fraenkel L et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108-1123. — link